| December 2019 |
| 12 Dec |
Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand |
 |
| 11 Dec |
Biocon Biologics Symposium on '100 years of Insulin - Delivering on Universal Access & Equitable Care' Resonates Well with Leading KOLs at IDF Congress 2019 |
|
| 03 Dec |
Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally |
|
| 03 Dec |
Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited |
|
| 02 Dec |
Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S. |
|
| November 2019 |
| 27 Nov |
USFDA Approves Biocon's sBLA for Pegfilgrastim New Manufacturing Facility |
|
| 18 Nov |
Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research |
|
| 12 Nov |
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year |
|
| 05 Nov |
Biocon's Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA |
|
| October 2019 |
| 28 Oct |
Biocon Moves Up to Rank No. 6 on Science Careers' Top 20 Global Pharma & Biotech Employers List 2019 |
|
| 23 Oct |
Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%;
Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3% |
|
| 10 Oct |
Biocon Biologics & Just - Evotec Biologics Sign Licensing Deal for a Biosimilar Asset |
|
| 03 Oct |
Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia |
|
| September 2019 |
| 26 Sep |
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs |
|
| 24 Sep |
Biocon Biologics Expands its R&D Footprint Through Acquisition |
|
| 20 Sep |
Company Statement: U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru |
|
| 12 Sep |
Biocon Licenses Three Generic Formulation Products to China Medical System Holdings |
|
| August 2019 |
| 31 Aug |
Company Statement: U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged
|
|
| 31 Aug |
Company Statement: U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru
|
|
| 22 Aug |
Biocon's Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
|
|
| 01 Aug |
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
|
|
| July 2019 |
| 25 Jul |
Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr; Small Molecules up 20% at Rs 480 Cr, Biologics Up 96% at Rs 490 Cr
|
|
| 08 Jul |
Company Statement: Pre -Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia |
|
| June 2019 |
| 14 Jun |
Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification |
|
| May 2019 |
| 22 May |
Health Canada Approves Biocon and Mylan's Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers |
|
| 16 May |
Biocon and Mylan to Present Final Overall Survival Data for Ogivri ™(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting |
|
| 07 May |
Company Statement: Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan |
|
| April 2019 |
| 25 Apr |
Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%;EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr Board Recommends 1: 1 Bonus Shares |
|
| March 2019 |
| 13 Mar |
Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia |
|
| 06 Mar |
Company Statement : Biocon Facility Completes Pre Approval U.S. FDA Inspection |
|
| 01 Mar |
Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited |
|
| February 2019 |
| 18 Feb |
Company Statement : Biocon Facilities complete Pre Approval U.S.FDA lnspection |
|
| 08 Feb |
Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S. |
|
| January 2019 |
| 24 Jan |
Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59% |
|
